News|Podcasts|January 30, 2026

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for Demodex Blepharitis

In this podcast, expert Mile Brujic, OD, FAAO, discusses the burden, diagnosis, and management of Demodex blepharitis, highlighting a recently approved targeted treatment option.

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, expert Mile Brujic, OD, FAAO, discusses the burden, diagnosis, and management of Demodex blepharitis, highlighting a recently approved targeted treatment option.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Summarize the disease burden in patients with Demodex blepharitis
  • Assess objective and subjective clinical findings to establish a diagnosis of Demodex blepharitis
  • Implement targeted therapies in treatment plans to eradicate Demodex and improve outcomes in patients with Demodex blepharitis

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Tarsus Pharmaceuticals, Inc.

Chair:

Mile Brujic, OD, FAAO

Premier Vision Group
Bowling Geen, OH

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: ABB Optical Group, AbbVie, Alcon, Apellis, Art Optical, Bausch + Lomb Health, Contamac, CooperVision, CS Eye, Dompé, Dopavision, Glaukos, Iveric Bio, Johnson & Johnson Vision Care, Lentechs, MDelite, Nordic Pharma, Notal Vision, Orasis, Radius XR, RVL, Sun Pharma, Tangible Science, Tarsus, Viatris, Visionix, Walman Optical, ZeaVision

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

Release Date

January 30, 2026

Expiration Date

January 30, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.


Latest CME